{"clinical_study": {"@rank": "83", "required_header": {"download_date": "ClinicalTrials.gov processed this data on April 06, 2020", "link_text": "Link to the current ClinicalTrials.gov record.", "url": "https://clinicaltrials.gov/show/NCT04335305"}, "id_info": {"org_study_id": "MedOPP376", "nct_id": "NCT04335305"}, "brief_title": "Checkpoint Blockade in COVID-19 Pandemic", "acronym": "COPERNICO", "official_title": "A Multicenter, Randomized, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Checkpoint Blockade in Patients With Coronavirus Disease 2019 (COVID-19)-Related Mild Acute Respiratory Syndrome Nonresponsive to Frontline Therapy", "sponsors": {"lead_sponsor": {"agency": "MedSIR", "agency_class": "Other"}}, "source": "MedSIR", "oversight_info": {"has_dmc": "No", "is_fda_regulated_drug": "No", "is_fda_regulated_device": "No"}, "brief_summary": {"textblock": "This is a prospective, multicenter, randomized, controlled, open-label, phase 2 clinical\n      trial"}, "detailed_description": {"textblock": "The aim of this study is to evaluate the efficacy of tocilizumab combined with pembrolizumab\n      (MK-3475) compared to standard care in adult patients with COVID-19 pneumonia and bad\n      prognostic factors who are nonresponsive to frontline therapy within 48 hours from treatment\n      initiation."}, "overall_status": "Not yet recruiting", "start_date": {"@type": "Anticipated", "#text": "March 30, 2020"}, "completion_date": {"@type": "Anticipated", "#text": "May 15, 2020"}, "primary_completion_date": {"@type": "Anticipated", "#text": "May 15, 2020"}, "phase": "Phase 2", "study_type": "Interventional", "has_expanded_access": "No", "study_design_info": {"allocation": "Randomized", "intervention_model": "Parallel Assignment", "primary_purpose": "Treatment", "masking": "None (Open Label)"}, "primary_outcome": {"measure": "Percentage of patients with normalization of SpO2 \u226596%", "time_frame": "through day 14 after study treatment initiation", "description": "Assessed by hospital records"}, "secondary_outcome": [{"measure": "Proportion of patients with temperature < 37,5 \u00b0C armpit.", "time_frame": "through day 14 after study treatment initiation", "description": "Assessed by hospital records"}, {"measure": "Proportion of patients discharged from the emergency department and classified as low risk", "time_frame": "In less than 28 days", "description": "Assessed by hospital records"}, {"measure": "Change from baseline in organ failure parameters", "time_frame": "Days 1, 3, 5, 7, 14 (+/- 1 day) and 28 (+/- 2 days) or until discharge whatever it comes first.", "description": "The clinical status will be assessed by the SOFA scores"}, {"measure": "Proportion of mortality rate", "time_frame": "Day 28", "description": "Determined as percentage of dead patients"}, {"measure": "Analysis of the remission of respiratory symptoms", "time_frame": "Up to 3 months after last dose of treatment", "description": "Determined as:\nTime to invasive mechanical ventilation (if not previously initiated);\nTime to independence from non-invasive mechanical ventilation;\nTime to independence from oxygen therapy."}, {"measure": "Evaluation of the radiological response", "time_frame": "at days 1 and 28 (+/- 2 days)", "description": "by using the same imaging technique (chest X-ray or thoracic CT scan)"}, {"measure": "Time to first negative in SARS-CoV-2 RT-PCR test", "time_frame": "within 28 days from study inclusion", "description": "determined using oropharyngeal or anal swabs"}, {"measure": "Change from baseline of ALC (absolute lymphocyte count),white blood cell count and white blood cell differential count", "time_frame": "days 3, 5, 7, 10, 14 and 28 after administration of study drug", "description": "Baseline defined as the value collected at day 1, 2 hours before treatment administration"}, {"measure": "Change from baseline of hemoglobin", "time_frame": "days 3, 5, 7, 10, 14 and 28 after administration of study drug", "description": "Baseline defined as the value collected at day 1, 2 hours before treatment administration"}, {"measure": "Change from baseline of platelets", "time_frame": "days 3, 5, 7, 10, 14 and 28 after administration of study drug", "description": "Baseline defined as the value collected at day 1, 2 hours before treatment administration"}, {"measure": "Change from baseline of activated partial thromboplastin time (aPTT)", "time_frame": "days 3, 5, 7, 10, 14 and 28 after administration of study drug", "description": "Baseline defined as the value collected at day 1, 2 hours before treatment administration"}, {"measure": "Change from baseline of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)", "time_frame": "days 3, 5, 7, 10, 14 and 28 after administration of study drug", "description": "Baseline defined as the value collected at day 1, 2 hours before treatment administration"}, {"measure": "Change from baseline of creatinine", "time_frame": "days 3, 5, 7, 10, 14 and 28 after administration of study drug", "description": "Baseline defined as the value collected at day 1, 2 hours before treatment administration"}, {"measure": "Change from baseline of glucose", "time_frame": "days 3, 5, 7, 10, 14 and 28 after administration of study drug", "description": "Baseline defined as the value collected at day 1, 2 hours before treatment administration"}, {"measure": "Change from baseline of total bilirubin", "time_frame": "days 3, 5, 7, 10, 14 and 28 after administration of study drug", "description": "Baseline defined as the value collected at day 1, 2 hours before treatment administration"}, {"measure": "Change from baseline of albumin", "time_frame": "days 3, 5, 7, 10, 14 and 28 after administration of study drug", "description": "Baseline defined as the value collected at day 1, 2 hours before treatment administration"}, {"measure": "Incidence of adverse events (AEs), incidence of prespecified AEs (safety and tolerability)", "time_frame": "Up to 28 days after last dose of treatment", "description": "Evaluated using the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v.5.0), SOFA scores."}], "number_of_arms": "2", "enrollment": {"@type": "Anticipated", "#text": "24"}, "condition": ["COVID-19", "Pneumonia, Viral"], "arm_group": [{"arm_group_label": "Tocilizumab plus Pembrolizumab (MK-3475)", "arm_group_type": "Experimental", "description": "Tocilizumab 8 mg/kg (up to a maximum of 800 mg per dose) as an intravenous infusion over 60 minutes; single dose Pembrolizumab (MK3475) 200 mg as an intravenous infusion over 30 minutes; single dose.\nPatients who are showing no clinical improvement in respiratory function after 12 hours could receive an additional dose of tocilizumab at the same dose level of the first administration. Patients who are showing SpO2 \u2264 94% on room air could receive an additional administration of pembrolizumab (MK-3475) at the same recommended dose after 3 weeks from treatment initiation and/or an additional dose of tocilizumab after 4 weeks from treatment initiation at physician's discretion."}, {"arm_group_label": "Continued Standard of Care", "arm_group_type": "No Intervention", "description": "Standard care per local written policies or guidelines comprises, as necessary and at physician's discretion, supplemental oxygen, noninvasive and invasive ventilation, antibiotic agents, vasopressor support, renal-replacement therapy, glucocorticoid, tocilizumab, virally targeted agents, chloroquine or hydroxychloroquine."}], "intervention": [{"intervention_type": "Drug", "intervention_name": "Tocilizumab", "description": "IV infusion over 60 minutes; 8 mg/kg (up to a maximum of 800 mg per dose); single dose", "arm_group_label": "Tocilizumab plus Pembrolizumab (MK-3475)", "other_name": ["Actemra", "RoActemra"]}, {"intervention_type": "Biological", "intervention_name": "Pembrolizumab (MK-3475)", "description": "IV infusion over 30 minutes, 200 mg; single dose", "arm_group_label": "Tocilizumab plus Pembrolizumab (MK-3475)", "other_name": ["MK-3475", "Keytruda"]}], "eligibility": {"criteria": {"textblock": "Inclusion Criteria:\n\n          1. Signed informed consent form (ICF) prior to participation in any study-related\n             activities.\n\n          2. Male or nonpregnant female patients \u2265 18 years at the time of signing ICF.\n\n          3. Laboratory confirmed COVID-19 infection defined with a positive reverse\n             transcription-polymerase chain reaction (RT-PCR) from any specimen and/or detection of\n             SARS-CoV-2 immunoglobulin (Ig)M/IgG antibodies.\n\n          4. Diagnostic confirmation of pneumonia by either chest X-ray or thoracic CT scan\n             (preferable).\n\n          5. Patient with severe acute respiratory syndrome related to COVID-19 under treatment as\n             per hospital protocol during at least 48 hours.\n\n          6. Patients with Sequential Organ Failure Assessment (SOFA) score \u2264 3 at the time of\n             signing ICF.\n\n          7. Patients hospitalized with fever defined as temperature \u2265 37,5 \u00b0C armpit.\n\n          8. Patients with total lymphocyte count \u22640,8 x106/mL.\n\n          9. Patients who are showing SpO2 \u2264 92% on room air and/or patient who are showing SpO2 \u2264\n             94% on room air and meet at least one of the following parameters:\n\n               -  No objective clinical improvement at physician's discretion after 48 hours of\n                  front-line standard care for COVID-19;\n\n               -  Decrease in lymphocyte count (any decrease within 48 hours);\n\n               -  Increase in ferritin levels (any increase within 48 hours);\n\n               -  Increase in IL-6 levels (any increase within 48 hours);\n\n               -  Increase in D-dimer levels (any increase within 48 hours);\n\n               -  Increase in CRP levels (any increase within 48 hours);\n\n               -  Increase in LDH levels (any increase within 48 hours);\n\n               -  Increase in ESR levels (any increase within 48 hours).\n\n         10. Life expectancy greater than 10 days.\n\n         11. Willing to take study medication and to comply with all study procedures.\n\n         12. In women of childbearing potential, negative pregnancy test and commitment to use\n             contraceptive method throughout the study.\n\n        Exclusion Criteria:\n\n          1. Participation in any other clinical trial of an experimental treatment for COVID-19.\n\n          2. Concurrent treatment with other agents with actual or possible direct acting antiviral\n             activity against SARS-CoV-2 is prohibited < 24 hours prior to study drug dosing,\n             except the commonly used antiviral drugs and/or chloroquine.\n\n          3. Requiring endotracheal intubation, mechanical ventilation, and extracorporeal membrane\n             oxygenation (ECMO) at screening.\n\n          4. Patients being treated with immunomodulators or anti-rejection drugs.\n\n          5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 x upper limit\n             of normal (ULN).\n\n          6. Creatinine clearance < 50 mL/min.\n\n          7. Chronic Obstructive Pulmonary Disease (COPD) or end-stage lung disease that require\n             home oxygen therapy.\n\n          8. Known hypersensitivity to recombinant proteins, or any excipient contained in the drug\n             formulation of study pembrolizumab and tocilizumab.\n\n          9. Treatment with high doses of systemic corticosteroids within 72 hours prior signing\n             the ICF except for inhaled steroids and prior corticosteroid therapy at dose lower\n             than or equal to 10 mg/day methylprednisolone equivalent.\n\n         10. Bowel diverticulitis or perforation.\n\n         11. Diagnosis of immunodeficiency receiving immunosuppressive therapy within seven days\n             prior to study treatment initiation. Active autoimmune disease that has required\n             systemic treatment in past 2 years (i.e., with use of disease modifying agents,\n             corticosteroids, or immunosuppressive drugs).\n\n         12. Current known infection with human immunodeficiency virus (HIV), hepatitis B virus\n             (HBV), or hepatitis C virus (HCV). Patients with past HBV infection or resolved HBV\n             infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a\n             positive hepatitis B core antibody [HBcAb] test, accompanied by a negative HBV DNA\n             test) are eligible. Patients positive for HCV antibody are eligible only if polymerase\n             chain reaction (PCR) is negative for HCV ribonucleic acid (RNA).\n\n         13. Vaccination with any live virus vaccine within 28 days prior to study treatment\n             initiation.\n\n             Note: Examples of live vaccines include, but are not limited to, the following:\n             measles, mumps, rubella, chicken pox/zoster, yellow fever, rabies, Bacillus\n             Calmette-Gu\u00e9rin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection\n             are generally killed virus vaccines and are allowed; however, intranasal influenza\n             vaccines (e.g., FluMist\u00ae) are live-attenuated vaccines and are not allowed.\n\n         14. History of prior allogeneic bone marrow, stem-cell, or solid organ transplantation.\n\n         15. Patients have any other concurrent severe medical condition that would, in the\n             Investigator's judgment contraindicate patient participation in the clinical study.\n\n         16. Pregnant women, lactating women and planned pregnant women."}, "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No"}, "overall_official": {"last_name": "Javier Cort\u00e9s", "role": "Study Chair", "affiliation": "IOB Institute of Oncology, Vall d\u00b4Hebron Institute of Oncology (VHIO)"}, "overall_contact": {"last_name": "Alicia Garc\u00eda", "phone": "+34 611 261 467", "email": "alicia.garcia@medsir.org"}, "verification_date": "March 2020", "study_first_submitted": "March 31, 2020", "study_first_submitted_qc": "April 2, 2020", "study_first_posted": {"@type": "Estimate", "#text": "April 6, 2020"}, "last_update_submitted": "April 2, 2020", "last_update_submitted_qc": "April 2, 2020", "last_update_posted": {"@type": "Estimate", "#text": "April 6, 2020"}, "responsible_party": {"responsible_party_type": "Sponsor"}, "condition_browse": {"mesh_term": ["Pneumonia, Viral", "Pneumonia"]}, "intervention_browse": {"mesh_term": "Pembrolizumab"}}}